Perspective Therapeutics reported initial responses in 50% of Cohort 3 patients and disease control in 95%. No dose-limiting toxicities or Grade 4 or 5 treatment-emergent events were reported, supporting a positive read, though more data are due in November.
These results suggest the treatment may control the disease for some patients without the most serious reported side effects. The report covers Cohort 3 only, and more findings are due in November, so the evidence is still early.
Follow Perspective Therapeutics, Inc. (CATX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CATX